73733-70-7

Basic information

• Product Name: ethyl 4-isothiocyanatopiperidine-1-carboxylate
• Synonyms: ethyl 4-isothiocyanatopiperidine-1-carboxylate;4-Isothiocyanato-1-piperidinecarboxylic acid ethyl ester
• CAS NO: 73733-70-7
• Molecular Formula: C₉H₁₄N₂O₂S
• Molecular Weight: 214.28466
• EINECS: 277-579-3
• Mol File: 73733-70-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 332.7°C at 760 mmHg
• Flash Point: 155°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 0.000144mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: ethyl 4-isothiocyanatopiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-isothiocyanatopiperidine-1-carboxylate(73733-70-7)
• EPA Substance Registry System: ethyl 4-isothiocyanatopiperidine-1-carboxylate(73733-70-7)

Safety Data

• Hazardous Substances Data: 73733-70-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H14N2O2S/c1-2-13-9(12)11-5-3-8(4-6-11)10-7-14/h8H,2-6H2,1H3

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 463-71-8 thiophosgene 
• 75-15-0 carbon disulfide 

Downstream Products

• 874536-41-1 C₁₆H₂₀F₃N₃O₃S 
• 75970-47-7 (1H-benzimidazol-2-yl)-(4-piperidinyl)amine dihydrobromide 
• 75970-64-8 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 
• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 75970-99-9 norastemizole 
• 1345012-53-4 (4-(2-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)ethyl)piperazin-1-yl)(1H-indol-2-yl)methanone 
• 1345012-52-3 tert-butyl 4-(2-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)ethyl)piperazine-1-carboxylate 
• 98244-76-9 {1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-(1-methyl-1H-benzoimidazol-2-yl)-amine 
• 98244-75-8 1-{2-[4-(1-Methyl-1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-ethyl}-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 79278-73-2 (1-Methyl-1H-benzoimidazol-2-yl)-(1-phenethyl-piperidin-4-yl)-amine 
• 75970-51-3 1-methyl-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 
• 73734-07-3 (1H-benzimidazol-2-yl)-(1-ethoxycarbonyl-piperidin-4-yl)amine 
• 73734-47-1 5-chloro-1-<(4-fluorophenyl)methyl>-N-<1-(2-phenylethyl)-4-piperidinyl>-1H-benzimidazol-2-amine 
• 75970-38-6 ethyl 4-<<6-fluoro-1-<(4-fluorophenyl)methyl>-1H-benzimidazol-2-yl>amino>-1-piperidinecarboxylate 

Relevant articles and documents

Synthesis and anti-Plasmodium activity of benzimidazole analogues structurally related to astemizole

A series of compounds structurally related to astemizole were designed and synthesized with the goal of determining their anti-Plasmodium activity. Several modifications of the astemizole structure, namely the removal of the 4-fluorobenzyl and/ or 4-methoxyphenethyl moieties, substitution of the benzene ring of the benzimidazole scaffold, replacement of the fluorine atom in the 4-fluorobenzyl group, and variation of the 4-aminopiperidine moiety, were explored. In vitro evaluation of the anti-Plasmodium activity of these compounds using the ItG strain showed that astemizole and some of its structurally similar derivatives have IC50 values in the nanomolar range and exhibit toxicity towards the parasite over Chinese ovarian hamster (CHO) cells with a selectivity as high as 200. The presence of a secondary cyclic amine at position 2 and substitution with chlorine at positions 4 and 5 in the benzimidazole moiety are two modifications that resulted in potent and selective antimalarials based on astemizole.

Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments

A compound of the formula wherein the substituents are as defined in the specification and pharmaceutical salts thereof having a good affinity for sub-types of melanocortin receptors making them useful for treating diseases in which such receptors are included such as pain, inflammatory conditions, etc.

Anti-histaminic benzimidazole, imidazopyridine and purine derivatives

Novel 1-alkyl substituted benzimidazole derivatives and their pharmaceutically acceptable acid addition salts having anti-histaminic properties, compositions containing the same, and methods of treating allergic diseases in warm-blooded animals.